DOCSLIB.ORG

Hanna Joleen 2018 Thesis.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hanna Joleen 2018 Thesis.Pdf Validation of an In Vitro Mutagenicity Assay Based on Pulmonary Epithelial Cells from the Transgenic MutaMouse: Intra-Laboratory Variability and Metabolic Competence By: Joleen Hanna, B.Sc. A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science In Biology Specializing in Chemical and Environmental Toxicology Supervisor: Dr. Paul White (University of Ottawa) Thesis Advisory Committee: Dr. Frances Pick (University of Ottawa) Dr. Iain Lambert (Carleton University) University of Ottawa Ontario, Canada March 2018 © Joleen Hanna, Ottawa, Canada, 2018 Abstract: Genetic toxicity tests used for regulatory screening must be rigorously validated to ensure accuracy, reliability and relevance. Hence, prior to establishment of an internationally- accepted test guideline, a new assay must undergo multi-stage validation. An in vitro transgene mutagenicity assay based on an immortalized cell line derived from MutaMouse lung (i.e., FE1 cells) is currently undergoing formal validation. FE1 cells retain a lacZ transgene in a λgt10 shuttle vector that can be retrieved for scoring of chemically-induced mutations. This work contributes to validation of the in vitro transgene (lacZ) mutagenicity assay in MutaMouse FE1 cells. More specifically, the work includes an intra-laboratory variability study, and a follow-up study to assess the endogenous metabolic capacity of FE1 cells. The former is essential to determine assay reliability, the latter to define the range of chemicals that can be reliably screened without an exogenous metabolic activation mixture (i.e., rat liver S9). The intra- laboratory variability assessment revealed minimal variability; thus, assay reproducibility can be deemed acceptable. Assessment of metabolic capacity involved exposure of FE1 cells to 5 known mutagens, and subsequent assessment of changes in the expression of genes involved in xenobiotic metabolism; induced transgene mutant frequency (±S9) was assessed in parallel. The results revealed that the FE1 cell line is capable of mobilising several Phase I and Phase II gene products known to be involved in the bioactivation of mutagens. Collectively, the results presented support the contention that the FE1 cell mutagenicity assay can be deemed reliable and reproducible. Consequently, the assay is an excellent candidate for continued validation, and eventual establishment of an OECD (Organization for Economic Cooperation and Development) Test Guideline. II Acknowledgements: Firstly, I must give an immense thank to my supervisor Dr. Paul A. White for being so enthusiastic and encouraging of my accomplishments, and supportive and approachable when things are difficult. I have learned and grown an incredible amount in your lab and can’t thank you enough for giving me the opportunity to take on this thesis. Thank you to my committee members Dr. Iain Lambert and Dr. Frances Pick for your helpful feedback and contributions, I am grateful to have you as advisors. My sincerest thank you to Rebecca Maertens for taking me under your wing, being so helpful and kind, letting me cry at you, all the edits and the countless little things you do to be supportive; I feel very fortunate to have you to depend on. Thank you to Julie Cox for all the tips, training, practice seminars, editing and most of all the pep talks and encouragement; you have been my biggest cheerleader and I am so grateful for your generosity. Thank you Matt Meier and Richard Webster for being such wonderful office mates, I’ve learned so much by just being in the same room with you. Thank you to my brilliant and impressive peers Jennifer Keir, Eunnara Cho, Marc Beal, Sarah Labib, Nikolai Chepelev, Francina Webster, John Wills, Clotilde Maurice and Alexandra Long for all their training, helpful hints and suggestions, being a wonderful audience for presentations, and all the laughs, rants and snacks. You have all been so supportive, willing to help and you made coming to the lab an easier option than moping at home; I can’t thank you enough for your friendship and encouragement. Thanks to Webster’s for hosting awesome parties. And a big thank you to all the people at MSD who provide an inspirational place to work and learn. III This research could not have been completed without the financial support from NSERC’s CREATE-REACT program, Health Canada’s Research Affiliate Program and the University of Ottawa. Thank you Samuel Clemont-Dupont, John Gingerich, Alexandra Long and Rebecca Maertens for your contributions as Operators 2-5 in the intra-laboratory variability study. I need to thank my friends and family for all their optimism and encouragement over the last 2 years. I am so grateful to my brothers, step-dad and family members for all their support in hard times, celebration in good and for making sure I don’t take things too seriously. An enormous thank you to my Mom for showing me what hard work and a strong woman look like; you continuously motivate me by watching you achieve the impossible. Thank you to my Dad for thinking I’m a rock star and instilling the Hanna confidence in me (or attitude depending on who you ask); I wish you were here but I know you would be the most proud. To Olaf, my fur-baby, thank you for the endless cuddles and keeping me smiling through the long days. To my forever, Jordan, the last two years have been some of our hardest, but swooning over you takes most of the stresses away. Thank you for your patience, love and support and for making sure that my diet consists of more than breakfast cereals. Thanks everyone! IV Table of Contents: Abstract.......................................................................................................................................... II Acknowledgements ...................................................................................................................... III Table of Contents .......................................................................................................................... V List of Tables ….......................................................................................................................... VIII List of Figures……........................................................................................................................... X List of Abbreviations .................................................................................................................. XIII Statement of Contributions....................................................................................................... XVII Chapter 1: Introduction ………………………………………………………………………………………………………..... 1 1.1 Brief History of Genotoxicity Assessment …………………………………………………………………………… 1 1.2 The Organisation for Economic Cooperation and Development (OECD) Test Guideline Program …………………………………………………………………………………………………………………………….. 7 1.3 Detection of Gene Mutations …………………………………………………………………………………………….. 9 1.3.1 In Vivo Transgenic Rodent (TGR) Systems .………………..………..…………………………………… 11 1.3.2 The MutaMouse FE1 Cell Line …..…………………………………………..………………………………… 13 1.3.2.1 Morphological Features and Growth Characteristics ………………………………….….. 13 1.3.2.2 Genetic and Biochemical Features ….……………………………………………………………… 14 1.3.2.3 Performance of the MutaMouse FE1 Cells Mutagenicity Assay ….………………….. 15 1.4 Organisation for Economic Cooperation and Development (OECD) Test Guideline Validation ………………………………………………………………………………………………………………………… 17 1.5 Requirement for the Development of In Vitro Alternatives …………………………………………….. 20 1.6 International Organizations Promoting the Development of In Vitro Assays ……………………. 22 1.7 Thesis Objectives ……………………………………………………………………………………………………………… 24 1.8 Tables and Figures …………………………………………………………………………………………………………… 25 1.9 References ………………………………………………………………………………………………………………………. 29 Chapter 2: Chapter 2: Intra-laboratory Variability in lacZ Mutant Frequency Values Generated Using the MutaMouse FE1 Cell in Vitro Transgene Mutation Assay ..……………………….………….. 33 2.1 Introduction …………………………………………………………………………………………………………………….. 35 2.2 Materials and Methods ……………………………………………………………………………………………………. 41 2.2.1 Chemicals …………….……..………………………………………………………………………………………….. 41 2.2.2 Cell Culture …………..………..……………………………………………………………………………………….. 42 2.2.3 FE1 Cell Transgene Mutation Assay …..……..……………………………………………………………… 42 2.2.4 Study Design ………………………………………..……..…………………………………………………………… 44 2.2.5 Data Analysis …..…………………………………..………………………………………………………………….. 45 2.3 Results …………………………………………………………………………………………………………………………….. 48 2.3.1 Analysis of Controls …………………………..…..……………………………………………………………….… 48 V 2.3.1.1 Negative Control Groups …….………………………………………………………………………….. 48 2.3.1.2 Positive Control Groups ……….…………………………………………………………………………. 49 2.3.2 Analysis of Test Chemicals ………..….………………………………………………………………………… 50 2.3.3 Comparison of Responses Across Operator and/or Test Date ….……………………………… 52 2.4 Discussion ………………………………………………………………………………………………………………………… 55 2.5 Tables and Figures …………………………………………………………………………………………………………… 71 2.6 Supplementary Data ………………………………………………………………………………………………………... 82 2.7 References ………….…………………………………………………………………………………………………………… 85 Chapter 3: Xenobiotic-induced Gene Expression Changes in MutaMouse FE1 Pulmonary Epithelial Cells …………………………………………………………………………………………………….…………………...…….. 92 3.1 Introduction …………………………………………………………………………………………………………………..… 94 3.2 Materials and Methods ………………………………………………………………………………………………..… 103 3.2.1 Chemicals ……………………………………….……………………………………………………………………. 103 3.2.2 Cell
Load more

Recommended publications
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Regulation of Xenobiotic and Bile Acid Metabolism by the Anti-Aging Intervention Calorie Restriction in Mice
    REGULATION OF XENOBIOTIC AND BILE ACID METABOLISM BY THE ANTI-AGING INTERVENTION CALORIE RESTRICTION IN MICE By Zidong Fu Submitted to the Graduate Degree Program in Pharmacology, Toxicology, and Therapeutics and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Dissertation Committee ________________________________ Chairperson: Curtis Klaassen, Ph.D. ________________________________ Udayan Apte, Ph.D. ________________________________ Wen-Xing Ding, Ph.D. ________________________________ Thomas Pazdernik, Ph.D. ________________________________ Hao Zhu, Ph.D. Date Defended: 04-11-2013 The Dissertation Committee for Zidong Fu certifies that this is the approved version of the following dissertation: REGULATION OF XENOBIOTIC AND BILE ACID METABOLISM BY THE ANTI-AGING INTERVENTION CALORIE RESTRICTION IN MICE ________________________________ Chairperson: Curtis Klaassen, Ph.D. Date approved: 04-11-2013 ii ABSTRACT Calorie restriction (CR), defined as reduced calorie intake without causing malnutrition, is the best-known intervention to increase life span and slow aging-related diseases in various species. However, current knowledge on the exact mechanisms of aging and how CR exerts its anti-aging effects is still inadequate. The detoxification theory of aging proposes that the up-regulation of xenobiotic processing genes (XPGs) involved in phase-I and phase-II xenobiotic metabolism as well as transport, which renders a wide spectrum of detoxification, is a longevity mechanism. Interestingly, bile acids (BAs), the metabolites of cholesterol, have recently been connected with longevity. Thus, this dissertation aimed to determine the regulation of xenobiotic and BA metabolism by the well-known anti-aging intervention CR. First, the mRNA expression of XPGs in liver during aging was investigated.
    [Show full text]
  • Flavin-Containing Monooxygenases: Mutations, Disease and Drug Response Phillips, IR; Shephard, EA
    Flavin-containing monooxygenases: mutations, disease and drug response Phillips, IR; Shephard, EA For additional information about this publication click this link. http://qmro.qmul.ac.uk/jspui/handle/123456789/1015 Information about this research object was correct at the time of download; we occasionally make corrections to records, please therefore check the published record when citing. For more information contact [email protected] Flavin-containing monooxygenases: mutations, disease and drug response Ian R. Phillips1 and Elizabeth A. Shephard2 1School of Biological and Chemical Sciences, Queen Mary, University of London, Mile End Road, London E1 4NS, UK 2Department of Biochemistry and Molecular Biology, University College London, Gower Street, London WC1E 6BT, UK Corresponding author: Shephard, E.A. ([email protected]). and, thus, contribute to drug development. This review Flavin-containing monooxygenases (FMOs) metabolize considers the role of FMOs and their genetic variants in numerous foreign chemicals, including drugs, pesticides disease and drug response. and dietary components and, thus, mediate interactions between humans and their chemical environment. We Mechanism and structure describe the mechanism of action of FMOs and insights For catalysis FMOs require flavin adenine dinucleotide gained from the structure of yeast FMO. We then (FAD) as a prosthetic group, NADPH as a cofactor and concentrate on the three FMOs (FMOs 1, 2 and 3) that are molecular oxygen as a cosubstrate [5,6]. In contrast to most important for metabolism of foreign chemicals in CYPs FMOs accept reducing equivalents directly from humans, focusing on the role of the FMOs and their genetic NADPH and, thus, do not require accessory proteins.
    [Show full text]
  • Type of the Paper (Article
    Supplementary Material A Proteomics Study on the Mechanism of Nutmeg-induced Hepatotoxicity Wei Xia 1, †, Zhipeng Cao 1, †, Xiaoyu Zhang 1 and Lina Gao 1,* 1 School of Forensic Medicine, China Medical University, Shenyang 110122, P. R. China; lessen- [email protected] (W.X.); [email protected] (Z.C.); [email protected] (X.Z.) † The authors contributed equally to this work. * Correspondence: [email protected] Figure S1. Table S1. Peptide fraction separation liquid chromatography elution gradient table. Time (min) Flow rate (mL/min) Mobile phase A (%) Mobile phase B (%) 0 1 97 3 10 1 95 5 30 1 80 20 48 1 60 40 50 1 50 50 53 1 30 70 54 1 0 100 1 Table 2. Liquid chromatography elution gradient table. Time (min) Flow rate (nL/min) Mobile phase A (%) Mobile phase B (%) 0 600 94 6 2 600 83 17 82 600 60 40 84 600 50 50 85 600 45 55 90 600 0 100 Table S3. The analysis parameter of Proteome Discoverer 2.2. Item Value Type of Quantification Reporter Quantification (TMT) Enzyme Trypsin Max.Missed Cleavage Sites 2 Precursor Mass Tolerance 10 ppm Fragment Mass Tolerance 0.02 Da Dynamic Modification Oxidation/+15.995 Da (M) and TMT /+229.163 Da (K,Y) N-Terminal Modification Acetyl/+42.011 Da (N-Terminal) and TMT /+229.163 Da (N-Terminal) Static Modification Carbamidomethyl/+57.021 Da (C) 2 Table S4. The DEPs between the low-dose group and the control group. Protein Gene Fold Change P value Trend mRNA H2-K1 0.380 0.010 down Glutamine synthetase 0.426 0.022 down Annexin Anxa6 0.447 0.032 down mRNA H2-D1 0.467 0.002 down Ribokinase Rbks 0.487 0.000
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • High-Altitude Adaptation in Rhesus Macaques 4 5 Zachary A
    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.19.104380; this version posted May 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Article Type: Letter 2 3 High-altitude adaptation in rhesus macaques 4 5 Zachary A. Szpiech† 6 Department of Biological Sciences 7 Auburn University 8 Auburn, AL 36842, USA 9 [email protected] 10 11 Taylor E. Novak* 12 Department of Biological Sciences 13 Auburn University 14 Auburn, AL 36842, USA 15 [email protected] 16 17 Nicholas P. Bailey* 18 Department of Biological Sciences 19 Auburn University 20 Auburn, AL 36842, USA 21 [email protected] 22 23 Laurie S. Stevison† 24 Department of Biological Sciences 25 Auburn University 26 Auburn, AL 36842, USA 27 [email protected] 28 29 †CorresponDence: [email protected], [email protected] 30 *Equal Contribution 31 32 Running Title: High-altitude adaptation in rhesus macaques 33 34 Keywords: Adaptation, high-altitude, EGLN1, selection, macaque, macaca mulatta 35 36 Abstract Word Count (300 max): 216 37 Total Word Count (5000 max): 3813 38 39 40 41 42 43 44 45 46 47 48 49 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.05.19.104380; this version posted May 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Glucocorticoids Are Not Always Deleterious for Bone
    CLINICAL VIGNETTE JBMR Glucocorticoids Are Not Always Deleterious for Bone Antoon HJM van Lierop, Neveen AT Hamdy, and Socrates E Papapoulos Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands ABSTRACT A 23-year-old man with the rare sclerosing bone disorder van Buchem disease presented with progressively worsening headaches that eventually became persistent and associated with papilledema. Increased intracranial pressure was diagnosed, and the patient had a ventriculoperitoneal drain inserted as well as simultaneously receiving treatment with prednisone. Before starting treatment, there was biochemical evidence for increased bone turnover and for steady increases in bone mineral density (BMD) at the spine and total hip despite the patient having reached his peak height of 197 cm at the age of 19 years. Treatment with prednisone for 2 years resulted in biochemical and histologic suppression of bone formation as well as of bone resorption and arrest of further bone accumulation. Our data suggest that glucocorticoids (GCs) may represent an attractive alternative to the high-risk surgical approaches used in the management of patients with progressive sclerosing bone disorders. Our findings also suggest that whereas sclerostin may not be required for the action of GCs on bone formation, it may well be important for the action of GCs on bone resorption. The exact mechanism by which sclerostin may be involved in the regulation of bone resorption is as yet to be explored. ß 2010 American Society for Bone and Mineral Research. KEY WORDS: BONE RESORPTION; BONE FORMATION; VAN BUCHEM DISEASE; PREDNISONE; SCLEROSTIN Introduction We present here sequential observations of a patient with van Buchem disease with life-threatening increased intracranial an Buchem disease is a rare bone sclerosing disorder pressure who was treated successfully with prednisone.
    [Show full text]
  • FMO3) As a Novel Genetic Determinant of Acetaminophen (APAP) Induced Hepatotoxicity Swetha Rudraiah University of Connecticut - Storrs, [email protected]
    University of Connecticut OpenCommons@UConn Doctoral Dissertations University of Connecticut Graduate School 8-4-2014 Characterization of Flavin-containing Monooxygenase-3 (FMO3) as a Novel Genetic Determinant of Acetaminophen (APAP) Induced Hepatotoxicity Swetha Rudraiah University of Connecticut - Storrs, [email protected] Follow this and additional works at: https://opencommons.uconn.edu/dissertations Recommended Citation Rudraiah, Swetha, "Characterization of Flavin-containing Monooxygenase-3 (FMO3) as a Novel Genetic Determinant of Acetaminophen (APAP) Induced Hepatotoxicity" (2014). Doctoral Dissertations. 506. https://opencommons.uconn.edu/dissertations/506 Characterization of Flavin-containing Monooxygenase-3 (FMO3) as a Novel Genetic Determinant of Acetaminophen (APAP) Induced Hepatotoxicity Swetha Rudraiah, Ph.D. University of Connecticut, 2014 Mice pretreated with a mild toxic dose of acetaminophen (APAP) acquire resistance to a second, higher APAP dose. This phenomenon is termed APAP autoprotection and the exact mechanism by which such resistance develops is not clearly known. Given the prevalence of APAP- hepatotoxicity and the human health impact of this potentially hepatotoxic agent, a further understanding of the mechanism(s) involved in such protection are of considerable significance and could lead to new modalities of treatment of acute drug-induced liver injury. The work presented in this thesis investigates FMO3 gene expression during APAP-induced liver injury as well as the functional significance of FMO3 over-expression during APAP- induced liver injury. Furthermore, FMO3 gene regulation during oxidative stress conditions is also examined. Acetaminophen treatment resulted in up-regulation of liver Fmo3 protein in male mice. Female mice express higher liver Fmo3 than males and are highly resistant to APAP hepatotoxicity.
    [Show full text]
  • 2018 Southern Regional Meeting
    Abstracts J Investig Med: first published as 10.1136/jim-2017-000697.1 on 1 February 2018. Downloaded from Cardiovascular club I Purpose of study Coronary artery disease (C.A.D.) is one of the highest causes of death in the world. The purpose of this 11:00 AM study is to compare Puerto Rico (P.R.), Hispanic, U.S.A. coun- try, with the U.S.A., in coronary artery disease. Thursday, February 22, 2018 Methods used Compare a population of Hispanics with the high LDL levels with normal total cholesterol and HDL in P. R. and the U.S.A. The study population was 1000 patients. 1 A POSSIBLE ROLE FOR GENETICS IN CARDIOVASCULAR The U.S.A. health statistics and P.R. Department of Health DISEASE AMONG THE ACADIANS was used for comparison. AE Tedesco*, Z Haq, KL Di Losa, MJ Ali, P Gregory. LSUHSC – New Orleans, New Orleans, Summary of results Studying the lipid profile of Puerto Rico LA population, we found that the mean value of LDL lipoprotein is high (±104 mg/dl) with similar cholesterol and HDL levels 10.1136/jim-2017-000697.1 in both societies; still the coronary disease (CAD) incidence is lower than the U.S.A. (20%–30%). Investigators from the U.P. Purpose of study It is well documented that the Louisiana Aca- R. reported the genetic admixture of this Hispanic population. ‘ ’ dians ( Cajuns ) experience a disproportionate risk for some They reported the admixture consisted of 3 genes called pro- genetic diseases due to a genetic founder effect.Furthermore, cer- tective against C.A.D.
    [Show full text]
  • Drosophila and Human Transcriptomic Data Mining Provides Evidence for Therapeutic
    Drosophila and human transcriptomic data mining provides evidence for therapeutic mechanism of pentylenetetrazole in Down syndrome Author Abhay Sharma Institute of Genomics and Integrative Biology Council of Scientific and Industrial Research Delhi University Campus, Mall Road Delhi 110007, India Tel: +91-11-27666156, Fax: +91-11-27662407 Email: [email protected] Nature Precedings : hdl:10101/npre.2010.4330.1 Posted 5 Apr 2010 Running head: Pentylenetetrazole mechanism in Down syndrome 1 Abstract Pentylenetetrazole (PTZ) has recently been found to ameliorate cognitive impairment in rodent models of Down syndrome (DS). The mechanism underlying PTZ’s therapeutic effect is however not clear. Microarray profiling has previously reported differential expression of genes in DS. No mammalian transcriptomic data on PTZ treatment however exists. Nevertheless, a Drosophila model inspired by rodent models of PTZ induced kindling plasticity has recently been described. Microarray profiling has shown PTZ’s downregulatory effect on gene expression in fly heads. In a comparative transcriptomics approach, I have analyzed the available microarray data in order to identify potential mechanism of PTZ action in DS. I find that transcriptomic correlates of chronic PTZ in Drosophila and DS counteract each other. A significant enrichment is observed between PTZ downregulated and DS upregulated genes, and a significant depletion between PTZ downregulated and DS dowwnregulated genes. Further, the common genes in PTZ Nature Precedings : hdl:10101/npre.2010.4330.1 Posted 5 Apr 2010 downregulated and DS upregulated sets show enrichment for MAP kinase pathway. My analysis suggests that downregulation of MAP kinase pathway may mediate therapeutic effect of PTZ in DS. Existing evidence implicating MAP kinase pathway in DS supports this observation.
    [Show full text]
  • Identification of Nondiabetic Heart Failure‑Associated Genes by Bioinformatics Approaches in Patients with Dilated Ischemic Cardiomyopathy
    2602 EXPERIMENTAL AND THERAPEUTIC MEDICINE 11: 2602-2608, 2016 Identification of nondiabetic heart failure‑associated genes by bioinformatics approaches in patients with dilated ischemic cardiomyopathy ANZHONG YU1, JINGYAO ZHANG2, HAIYAN LIU3, BING LIU1 and LINGDONG MENG1 1Department of Cardiology, Jinan No. 4 People's Hospital, Jinan, Shandong 250031; 2Department of Blood Purification, Jinan Infectious Disease Hospital, Jinan, Shandong 250021; 3Department of Internal Medicine, Jinan Minzu Hospital, Jinan, Shandong 250014, P.R. China Received January 26, 2015; Accepted March 3, 2016 DOI: 10.3892/etm.2016.3252 Abstract. Heart failure (HF) is a common pathological conclusion, the two DEGs, NPPA and SERPINE1, may be condition affecting 4% of the worldwide population. important in the pathogenesis of HF and may be used for the However, approaches for predicting or treating nondiabetic diagnosis and treatment of HF. HF (ND-HF) progression are insufficient. In the current study, the gene expression profile GSE26887 was analyzed, Introduction which contained samples from 5 healthy controls, 7 diabetes mellitus-HF patients and 12 ND-HF patients with dilated Heart failure (HF), also known as chronic HF, is one of the ischemic cardiomyopathy. The dataset of 5 healthy controls major causes of mortality affecting approximately 4% of the and 12 ND-HF patients was normalized with robust multichip world's population, while the prevalence of this condition is average analysis and the differentially expressed genes (DEGs) currently increasing (1,2). In addition to the widely known were screened by unequal variance t-test and multiple-testing risk factor of glucose abnormalities (observed in ~43% of HF correction. In addition, the protein-protein interaction patients) (3), HF can also result from certain other factors, (PPI) network of the upregulated and downregulated genes which is classified as nondiabetic HF (ND‑HF) and is based was constructed using the Search Tool for the Retrieval of on a complicated pathological mechanism (4,5).
    [Show full text]